Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pentetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.48 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.43 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL17747958 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL136882 | 0.97 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL2170101 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL29687451 | 0.95 | KDM4E (0.74) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL7071979 | 0.95 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL1477452 | 0.95 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL1714086 | 0.95 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL8374505 | 0.95 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL16004809 | 0.95 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL978169 | 0.95 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20210299169-A1 | Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage | UNM RAINFOREST INNOVATIONS | 2021-09-30 | — | — | US | claimed |
| WO-2026102309-A1 | SELECTIVE RADIOTRACERS AND METHODS OF USE | LUTROO IMAGING, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4694940-A1 | STEAP2-TARGETED COMPOUNDS AND USE THEREOF | Astrazeneca AB (SE) | 2026-02-18 | — | — | EP | disclosed |
| US-20250352676-A1 | N-Cyclopropyl-1-(4-(4-(Fluoro-18f)Phenyl)Pyrimidin-5-Yl)-N-Methylpiperidine- 4-Carboxamide and Uses in PET Imaging | UNIV EMORY (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2024212001-A9 | 2,4-DIHYROXY-5-ISOPROPYLPHENYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF EFFECTIVE AS EXTRACELLULAR HSP90, (EHSP90)-TARGETED RADIOPHARMACEUTICALS USEFUL IN THE TREATMENT OF CANCER | Fusion Pharmaceuticals Inc. (CA) | 2025-06-19 | — | — | WO | disclosed |
| CN-119701863-A | Application of iron doped nano hydroxyapatite in preparation of radionuclide internal pollution emission promoting agent | 西南科技大学 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024216389-A9 | CLAUDIN 18.2-TARGETED COMPOUNDS AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024211999-A9 | EXTRACELLULAR HSP90 (EHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2025-01-16 | — | — | WO | disclosed |
| US-20240408249-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-12-12 | — | — | US | disclosed |
| US-20240350682-A1 | STEAP2-TARGETED COMPOUNDS AND USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-24 | — | — | US | disclosed |
| WO-2023050008-A9 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024044755-A2 | EXTRACELLULAR HSP90 (EHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2024-02-29 | — | — | WO | disclosed |
| US-20230158178-A1 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | UNIV EMORY (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023070202-A1 | CLAUDIN 18.2-TARGETED COMPOUNDS AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023050008-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-04-06 | — | — | WO | disclosed |
| US-20220306663-A1 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | UNIV EMORY (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | EMORY UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210299169-A1 | Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage | UNM RAINFOREST INNOVATIONS | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350682-A1 | STEAP2-TARGETED COMPOUNDS AND USE THEREOF | CD47, CD2BP2, SPAG5 | CHRM2 4800/4885ADRA2A 3401/4885SLC6A2 1598/4885 |
| US-20220306663-A1 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | SLC16A8, S100A8, FGF23 | CHRM2 2743/4885ADRA2A 3591/4885SLC6A2 1916/4885 |
| US-20240408249-A1 | EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF | EGFR, ERBB3, ERBB2 | CHRM2 4865/4885ADRA2A 4658/4885SLC6A2 4525/4885 |
| US-20230158178-A1 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | AFF1, METTL3, VHL | CHRM2 4150/4885ADRA2A 1916/4885SLC6A2 3535/4885 |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | SLC16A8, S100A8, FGF23 | CHRM2 2743/4885ADRA2A 3591/4885SLC6A2 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.